The objective of this Phase 4 study is to evaluate the persistence of antibody responses (determined by a serum bactericidal assay using human complement (SBA-HC)) approximately 4 years after the administration of a booster dose of Menactra vaccine in trial MTA77.

Results

The results for this interventional study can be found here.